Acetyl-EEF1A1 (K41) Antibody

What is EEF1A1 and why is its acetylation at K41 significant?

EEF1A1 (Eukaryotic elongation factor 1A1) is canonically involved in protein synthesis but also possesses several noncanonical functions in diverse cellular processes. The acetylation at lysine 41 (K41) is particularly significant as it represents one of the 20 putative acetylation sites on EEF1A1 and influences the protein's subcellular localization and function. This specific modification affects EEF1A1's interactions with binding partners and impacts various cellular processes including metabolism and gene regulation .

Methodologically, researchers investigating this modification should consider:

• Subcellular fractionation to determine localization changes upon acetylation

• Co-immunoprecipitation assays to identify modified interaction partners

• Site-directed mutagenesis (K41Q for acetylation mimicking, K41R for preventing acetylation) to study functional consequences

How does EEF1A1 differ from EEF1A2, and do their acetylation patterns differ?

EEF1A1 and EEF1A2 are isoforms with distinct tissue distribution and functional differences. While EEF1A1 is ubiquitously expressed in most tissues, EEF1A2 shows tissue-specific expression. Notably, their acetylation patterns differ significantly - HDAC1/2 inhibition using mocetinostat in primary Schwann cell cultures leads to strongly increased levels of Ac-eEF1A1, but not of Ac-eEF1A2 .

A key structural difference relevant to acetylation is at position 273 - in EEF1A1 this is a lysine (K) that can be acetylated, while in EEF1A2 it's an arginine (R) that prevents acetylation at this position . This difference directly impacts their respective functions and regulation mechanisms.

What are the optimal experimental conditions for using Acetyl-EEF1A1 (K41) antibody in Western blotting?

For optimal Western blotting using Acetyl-EEF1A1 (K41) antibody:

Recommended protocol:

• Dilution range: 1:500-1:2000 for Western blotting

• Buffer composition: PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide

• Secondary antibody: Anti-rabbit IgG (based on the host species)

• Blocking: 5% non-fat milk or BSA in TBST

• Visualization: ECL detection system

Critical considerations:

• Include positive controls (samples treated with deacetylase inhibitors like mocetinostat)

• Include negative controls (samples treated with HDAC activators)

• For specificity validation, include mutant K41R samples that cannot be acetylated at this position

• Normalize loading using total EEF1A1 antibody on stripped membranes

When troubleshooting weak signals, consider enriching acetylated proteins through immunoprecipitation prior to Western blotting, as acetylation can be transient and occur at substoichiometric levels.

How can I validate the specificity of Acetyl-EEF1A1 (K41) antibody in my experimental system?

Methodological approach to validating antibody specificity:

• Pharmacological treatment validation:

  • Treat cells with HDAC inhibitors (e.g., mocetinostat) to increase acetylation levels

  • Compare with vehicle-treated controls

  • Expected result: Increased signal in inhibitor-treated samples

• Genetic validation approaches:

  • Express wild-type EEF1A1 vs. K41R mutant (acetylation-resistant)

  • Expected result: Signal present in wild-type but absent in K41R samples

  • Alternatively, perform HDAC1/2 knockdown to increase acetylation levels

• Peptide competition assay:

  • Pre-incubate antibody with acetylated and non-acetylated peptides

  • Expected result: Specific signal blocked only by acetylated peptide

• Mass spectrometry correlation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm K41 acetylation in the immunoprecipitated samples

These approaches should be used in combination for comprehensive validation of antibody specificity.

How does acetylation alter EEF1A1's subcellular localization and function?

Acetylation significantly impacts EEF1A1's subcellular distribution and functional properties:

Subcellular localization changes:

• While non-acetylated EEF1A1 is predominantly cytoplasmic, Ac-eEF1A1 is localized in both nuclear and cytoplasmic fractions

• Mutation studies demonstrate that acetylation-mimicking mutations (K to Q) at positions K41, K179, and K273 increase nuclear localization of EEF1A1

• Among these sites, K273Q mutation was most efficient at promoting nuclear localization

Functional consequences:

• Nuclear Ac-eEF1A1 interacts with transcription factors such as Sox10, affecting their stability and function

• This interaction with Sox10 is potentiated by HDAC1/2 inhibition in the nuclear compartment

• Acetylated EEF1A1 promotes Sox10 re-localization to the cytoplasm and increases co-localization with the proteasome, ultimately decreasing Sox10 levels

The mechanism appears to involve acetylation-dependent shuttling between cytoplasmic and nuclear compartments, with different acetylation sites contributing differentially to this process and subsequent protein-protein interactions.

What is the relationship between EEF1A1 acetylation and cellular metabolism?

EEF1A1 serves as a critical regulator of cellular metabolism through acetylation-dependent mechanisms:

Metabolic impacts of EEF1A1:

• EEF1A1 deficiency reduces glycolysis, increases fatty acid oxidation, and increases neutral lipid storage

• EEF1A1-deficient cells show a shift toward oxidative metabolism to support cell proliferation and migration

Mechanism:

• Transcriptomic analysis reveals reduced NFKB and MYC signaling in EEF1A1-deficient cells

• Decreased hexokinase expression and activity occurs with EEF1A1 deficiency, contributing to glycolytic defects

• These metabolic changes suggest that acetylation status of EEF1A1 may influence its role in metabolic regulation

Researchers investigating this relationship should consider:

• Metabolic flux analysis to measure glycolysis and oxidative phosphorylation rates

• Isotope tracing to track carbon sources in EEF1A1 wild-type vs. acetylation site mutants

• Assessment of metabolic enzyme activities in response to changes in EEF1A1 acetylation status

How should I design experiments to investigate the role of EEF1A1 acetylation in transcriptional regulation?

Experimental design framework:

• Modulation of EEF1A1 acetylation status:

  • Pharmacological approach: Treat cells with HDAC inhibitors (e.g., mocetinostat) vs. vehicle control

  • Genetic approach: Generate acetylation-mimicking (K41Q, K179Q, K273Q) and acetylation-preventing (K41R, K179R, K273R) mutants

  • Create combinations of mutations to assess synergistic effects

• Transcriptional analysis methods:

  • RNA-seq to identify global transcriptional changes

  • ChIP-seq to detect altered chromatin association patterns

  • Nascent RNA labeling (e.g., EU-seq) to distinguish direct transcriptional effects from RNA stability changes

• Protein interaction studies:

  • Immunoprecipitation followed by mass spectrometry to identify differential protein interactions based on acetylation status

  • Focus on interactions with transcription factors (e.g., Sox10)

  • BioID or APEX proximity labeling to identify compartment-specific interaction partners

• Cellular localization assessment:

  • Perform subcellular fractionation followed by Western blotting

  • Live-cell imaging with fluorescently tagged EEF1A1 variants

  • Quantify nuclear/cytoplasmic ratios under different conditions

• Functional validation:

  • Reporter assays using promoters of identified target genes

  • CRISPR-based transcriptional modulation assays

  • Rescue experiments in EEF1A1-depleted cells

This comprehensive approach enables rigorous investigation of acetylation-dependent transcriptional regulation.

What controls should be included when studying EEF1A1 acetylation in different cell types?

Essential controls for studying EEF1A1 acetylation:

• Cell type-specific controls:

  • Verify endogenous expression levels of EEF1A1 vs. EEF1A2 (may vary by tissue)

  • Determine baseline acetylation status across cell types

  • Assess HDAC1/2 expression levels, as they are key regulators of EEF1A1 acetylation

• Treatment validation controls:

  • For HDAC inhibitor studies: Confirm inhibitor efficacy using global histone acetylation markers

  • Include time-course analyses to capture transient acetylation changes

  • Use multiple HDAC inhibitors with different specificities to confirm consistency

• Antibody controls:

  • Include peptide competition controls with acetylated and non-acetylated peptides

  • Use multiple antibodies targeting different acetylated sites when possible

  • Include genetic knockouts or knockdowns as negative controls

• Sample preparation controls:

  • Add deacetylase inhibitors to lysis buffers to prevent post-lysis deacetylation

  • Match cell density and growth conditions across experimental groups

  • Control for cell cycle phase, as acetylation patterns may vary during the cell cycle

• Data analysis controls:

  • Normalize acetylated EEF1A1 signal to total EEF1A1 levels

  • Use appropriate statistical tests for comparing acetylation across conditions

  • Include biological replicates (minimum n=3) to account for variation

Implementing these controls ensures robust and reliable interpretation of EEF1A1 acetylation data across different experimental systems.

How can I simultaneously detect multiple acetylation sites on EEF1A1?

Comprehensive approach to multi-site acetylation detection:

• Mass spectrometry-based approaches:

  • Enrich acetylated peptides using anti-acetyllysine antibodies prior to MS analysis

  • Apply parallel reaction monitoring (PRM) for targeted detection of specific acetylated peptides

  • Implement SILAC or TMT labeling to quantify changes across multiple acetylation sites

  • Example protocol: After immunoprecipitation of EEF1A1, perform on-bead digestion with trypsin, followed by LC-MS/MS analysis with acetyllysine as a variable modification

• Custom antibody panels:

  • Utilize site-specific antibodies for different acetylation sites (K41, K179, K273)

  • Perform sequential immunoblotting with different acetylation site-specific antibodies

  • Consider multiplexed detection using differently labeled secondary antibodies

• Mutational analysis:

  • Generate single and combinatorial K→R or K→Q mutations

  • Compare migration patterns on Phos-tag or standard SDS-PAGE gels

  • Assess functional outcomes of different acetylation patterns

• In situ detection:

  • Employ proximity ligation assays (PLA) with pairs of antibodies

  • One targeting total EEF1A1 and others targeting specific acetylation sites

  • This approach provides spatial information about acetylation patterns

A comprehensive experimental strategy would integrate these approaches to create a complete acetylation profile of EEF1A1 under various conditions.

What are the best approaches to study the dynamics of EEF1A1 acetylation in response to cellular stimuli?

Methodological approaches for studying acetylation dynamics:

• Temporal resolution strategies:

  • Time-course experiments with short intervals (minutes to hours)

  • Pulse-chase labeling with heavy isotope-labeled lysine to track newly acetylated proteins

  • Live-cell imaging using acetylation-sensitive fluorescent reporters

• Stimulus-specific considerations:

  • For stress responses: Determine baseline acetylation and apply controlled stressors

  • For growth factor stimulation: Use serum starvation followed by specific growth factor addition

  • For metabolic changes: Manipulate nutrient availability and measure acetylation changes

• Acetylation turnover measurement:

  • Use HDAC inhibitors to block deacetylation and measure accumulation rates

  • Apply mathematical modeling to derive acetylation/deacetylation rate constants

  • Compare half-lives of acetylation at different sites (K41, K179, K273)

• Spatial dynamics analysis:

  • Employ subcellular fractionation at multiple timepoints

  • Use fluorescence recovery after photobleaching (FRAP) with acetylation-mimetic mutants

  • Track nuclear-cytoplasmic shuttling in real-time with fluorescently tagged proteins

• Multiplexed detection methods:

  • Single-cell analysis to capture cell-to-cell variation in acetylation dynamics

  • CyTOF or multiplexed imaging to correlate EEF1A1 acetylation with other cellular parameters

  • Integrated omics approaches (acetylomics, proteomics, transcriptomics) to capture system-wide changes

These approaches allow researchers to construct detailed models of EEF1A1 acetylation dynamics and their functional consequences in response to various cellular conditions and stimuli.

How is EEF1A1 acetylation implicated in disease processes, and what methodologies can detect these alterations?

Disease associations and detection methodologies:

• Neurological disorders:

  • EEF1A1 acetylation levels are altered in Schwann cells during de-differentiation in culture and in sciatic nerves after lesion

  • Detection method: Immunohistochemistry of nerve tissue sections with Acetyl-EEF1A1 (K41) antibody

  • Analytical approach: Compare acetylation levels between healthy and diseased nerve tissues

• Cancer biology:

  • EEF1A1 regulates metabolic substrate preference, with implications for cancer metabolism

  • EEF1A1 is identified as a cervical cancer suppressor (CCS3)

  • Detection method: Western blotting of tumor vs. normal tissue lysates

  • Quantification: Determine acetylated/total EEF1A1 ratio and correlate with disease stage

• Metabolic disorders:

  • EEF1A1 deficiency affects glycolysis and fatty acid oxidation, suggesting a role in metabolic regulation

  • Detection method: Combined metabolomic and acetylation profiling

  • Analysis approach: Correlate acetylation patterns with altered metabolic parameters

• Research methodologies for clinical samples:

  • Tissue microarray analysis with site-specific acetylation antibodies

  • Laser capture microdissection followed by acetylation-specific Western blotting

  • Single-cell proteomics to identify cell-type specific acetylation changes within heterogeneous tissues

These approaches enable investigation of EEF1A1 acetylation as both a biomarker and potential therapeutic target in various disease contexts.

What experimental approaches can determine if EEF1A1 acetylation status affects response to therapeutic agents?

Experimental framework for therapeutic investigations:

• Drug sensitivity correlation studies:

  • Establish cell lines with EEF1A1 wild-type, acetylation-mimetic (K→Q), and acetylation-resistant (K→R) mutants

  • Perform drug sensitivity screening across therapeutic classes

  • Analysis: Compare IC50 values and identify drugs with differential efficacy based on acetylation status

• Combination therapy assessment:

  • Test HDAC inhibitors (to increase EEF1A1 acetylation) in combination with other therapeutic agents

  • Measure synergistic, additive, or antagonistic effects using Chou-Talalay method

  • Determine if pretreatment with HDAC inhibitors sensitizes cells to subsequent therapies

• Mechanism investigation:

  • Perform RNA-seq and proteomics on cells with different EEF1A1 acetylation states before and after drug treatment

  • Map changes to specific signaling pathways and cellular processes

  • Focus on metabolic response pathways, given EEF1A1's role in metabolism

• In vivo validation:

  • Generate xenograft models with different EEF1A1 acetylation states

  • Evaluate tumor growth and response to therapy

  • Analyze tissue samples for in vivo acetylation status correlation with treatment outcome

• Biomarker development:

  • Develop assays to quantify EEF1A1 acetylation in patient samples

  • Correlate pretreatment acetylation levels with treatment outcomes

  • Assess potential for EEF1A1 acetylation as a companion diagnostic

This systematic approach can identify novel therapeutic strategies based on EEF1A1 acetylation status and potentially lead to personalized treatment approaches.

How do different antibody preparation methods affect the specificity and sensitivity of Acetyl-EEF1A1 (K41) antibody detection?

Critical technical aspects of antibody performance:

Optimization strategies:

• For Western blotting: Determine optimal antibody concentration (recommended 1:500-1:2000)

• For immunoprecipitation: Use excess antibody with optimized bead ratios

• For ELISA applications: Establish standard curves with acetylated peptides (recommended dilution 1:20000)

The antibody preparation significantly impacts experimental outcomes and should be carefully considered based on the specific research application and required sensitivity.

What are the technical challenges in studying the interplay between EEF1A1 acetylation and other post-translational modifications?

Methodological challenges and solutions:

• Cross-talk detection challenges:

  • EEF1A1 has multiple PTM sites, including acetylation, phosphorylation, methylation, and ubiquitylation

  • Traditional antibody-based methods detect only one modification at a time

  • Solution: Apply tandem mass spectrometry with electron transfer dissociation (ETD) to preserve labile modifications

• PTM hierarchy determination:

  • Different modifications may occur in specific sequences or compete for the same residues

  • Approach: Generate modification-specific mutants and assess downstream modification patterns

  • Method: Time-course studies with inhibitors of specific modifying enzymes

• Spatial regulation analysis:

  • Different compartments may have distinct modification patterns

  • Technique: Subcellular fractionation followed by modification-specific detection

  • Imaging approach: Multi-color immunofluorescence with modification-specific antibodies

• Enzymatic regulation complexity:

  • Writers, readers, and erasers for different PTMs form complex regulatory networks

  • Experimental design: Systematic knockdown/inhibition of modifying enzymes

  • Analysis: Network modeling of PTM interactions based on quantitative data

• Technical solutions for multi-PTM detection:

  • Middle-down proteomics for analysis of larger protein fragments with multiple modifications

  • Sequential enrichment strategies for different PTMs

  • Targeted proteomics (PRM/MRM) focused on known modification sites

These advanced technical approaches enable comprehensive investigation of the complex PTM landscape of EEF1A1 and its functional consequences.

What emerging technologies could enhance the study of EEF1A1 acetylation in complex biological systems?

Innovative methodological approaches:

• CRISPR-based acetylation site editing:

  • Application: Precise modification of endogenous EEF1A1 acetylation sites

  • Advantage: Studies modifications in physiological context without overexpression

  • Implementation: Base editors or prime editors targeting specific lysine codons

• Single-molecule tracking of acetylation dynamics:

  • Application: Real-time visualization of EEF1A1 acetylation and localization

  • Technology: Site-specific incorporation of acetyllysine using genetic code expansion

  • Analysis: Correlate acetylation status with mobility and interaction kinetics

• Spatial proteomics of acetylated EEF1A1:

  • Application: Map subcellular distribution of differently acetylated EEF1A1 forms

  • Method: Hyperplexed imaging mass cytometry with multiple PTM-specific antibodies

  • Output: Subcellular acetylation maps across different cellular states

• Acetylation-dependent interactome mapping:

  • Application: Define differential binding partners based on acetylation status

  • Technology: BioID or APEX tagging of acetylation-mimetic mutants

  • Analysis: Quantitative proteomics to identify acetylation-dependent interactions

• Integrated multi-omics approaches:

  • Application: Connect EEF1A1 acetylation to transcriptome, proteome, and metabolome

  • Implementation: Single-cell multi-omics technologies

  • Advantage: Captures cellular heterogeneity in acetylation responses

These emerging technologies will provide unprecedented insights into EEF1A1 acetylation biology and potentially reveal new therapeutic opportunities.

How might computational approaches improve the prediction and functional analysis of EEF1A1 acetylation sites?

Computational strategies and applications:

• Machine learning for acetylation site prediction:

  • Input data: Protein sequence contexts, structural features, and evolutionary conservation

  • Model types: Deep learning algorithms trained on known acetylation datasets

  • Application: Prediction of novel acetylation sites beyond the 20 currently identified sites

• Molecular dynamics simulations:

  • Approach: Compare conformational dynamics of acetylated vs. non-acetylated EEF1A1

  • Analysis: Identify allosteric changes induced by acetylation

  • Application: Predict how K41, K179, and K273 acetylation affects protein-protein interactions

• Systems biology modeling:

  • Implementation: Integrate acetylation data into protein interaction networks

  • Analysis: Identify acetylation-dependent network perturbations

  • Application: Predict cellular outcomes of altered acetylation patterns

• PTM crosstalk prediction:

  • Approach: Statistical analysis of co-occurring modifications

  • Tool development: Algorithms to predict modification interdependencies

  • Validation: Targeted mass spectrometry to confirm predicted modification patterns

• Structure-based drug design:

  • Application: Development of compounds that specifically target acetylated EEF1A1

  • Method: Virtual screening against structural models of differently acetylated EEF1A1

  • Output: Candidate molecules for experimental validation

These computational approaches complement experimental methods and accelerate discovery in EEF1A1 acetylation research, particularly for complex systems where experimental validation is challenging.